https://www.db-thueringen.de/receive/dbt_mods_00066812https://www.db-thueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00068459/CHEM_CHEM202501037.pdfhttps://www.db-thueringen.de/rsc/thumbnail/dbt_mods_00066812.png text article In Vitro Psilocybin Synthesis by Co‐Immobilized Enzymes Schäfer, Tim Schäfer Tim Pharmaceutical Microbiology Friedrich Schiller University Beutenbergstrasse 11a Jena Germany Pharmaceutical Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author 1299220282 article Sherwood, Alexander Sherwood Alexander The Usona Institute 2780 Woods Hollow Road Madison WI USA aut Author Kirkland, Thomas Kirkland Thomas Research & Development Promega Corporation 2800 Woods Hollow Road Madison WI USA aut Author Krüger, Thomas Krüger Thomas Molecular and Applied Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author 142208159 Worbs, Jakob Worbs Jakob Pharmaceutical Microbiology Friedrich Schiller University Beutenbergstrasse 11a Jena Germany Pharmaceutical Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author urn:nbn:de:gbv:27-dbt-66812-6 Kniemeyer, Olaf Kniemeyer Olaf Molecular and Applied Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author 1146436270 Gressler, Markus Gressler Markus Pharmaceutical Microbiology Friedrich Schiller University Beutenbergstrasse 11a Jena Germany Pharmaceutical Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author 1072725606 Hoffmeister, Dirk Hoffmeister Dirk Pharmaceutical Microbiology Friedrich Schiller University Beutenbergstrasse 11a Jena Germany Pharmaceutical Microbiology Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute Beutenbergstrasse 11a Jena Germany aut Author 124018092 10.1002/chem.202501037 2025-05-22 31 29 e202501037 1 7 continuingjournal journal Chemistry – A European Journal Chem. Eur. J. 0947-6539 1521-3765 http://uri.gbv.de/document/gvk:ppn:270935193 1478547-X text 1995 Weinheim Wiley-VCH en 540 Advanced clinical trials investigate the Psilocybe magic mushroom natural product psilocybin as a treatment against major depressive disorder. Currently, synthetic material is used to meet the demand for legitimate pharmaceutical purposes. Here, we report an in vitro approach to biocatalytically produce psilocybin on a solid‐phase matrix charged with five covalently bound biosynthetic enzymes. These enzymes include three Psilocybe enzymes: IasA*, an engineered l ‐tryptophan decarboxylase/aromatic aldehyde synthase, the 4‐hydroxytryptamine kinase PsiK and the norbaeocystin methyltransferase PsiM, along with Escherichia coli nucleosidase MtnN and adenine deaminase Ade. In a proof‐of‐principle experiment, this enzyme‐charged resin allowed for quantitative turnover of 4‐hydroxy‐ l ‐tryptophan into psilocybin. This facile process i) represents a sustainable approach with reusable enzymes, ii) circumvents the drawbacks of in vivo processes while harnessing the selectivity of enzymatic catalysis and iii) helps access an urgently needed drug candidate. biotechnology enzyme immobilization natural products psilocybin en 7 Seiten 540 his Host institution bibliography Zweitveröffentlichung dbt_mods_00066812https://www.db-thueringen.de/receive/dbt_mods_00066812